Mitigating gut immune adverse effects in CTLA-4 blockade for antitumor efficacy

作     者：Shijun He Jianping Zuo Zemin Lin 

作者机构：Laboratory of ImmunopharmacologyState Key Laboratory of Drug ResearchShanghai Institute of Materia MedicaChinese Academy of SciencesShanghai 201203China Innovation Research Institute of Traditional Chinese MedicineShanghai University of Traditional Chinese MedicineShanghai 201203China School of PharmacyUniversity of Chinese Academy of SciencesBeijing 100049China 

出 版 物：《Science China(Life Sciences)》 (中国科学（生命科学英文版）)

年 卷 期：2024年第67卷第7期

页      面：1539-1541页

核心收录：

学科分类：0710[理学-生物学] 1002[医学-临床医学] 10[医学] 

基　　金：supported by the National Natural Science Foundation of China(82374108) Shanghai Municipal Science and Technology Major Project(TM202301D003)。 

主　　题：al. immune gastrointestinal 

摘      要：By creating an immune checkpoint blockade-induced colitis model,Lo et al.(2024)have suggested a strategy for alleviating gastrointestinal immune-related adverse events while preserving the antitumor stimulatory effects of CTLA-4 blockade within this microbiota-dependent model.